Recombinant human thyroid stimulating hormone in 2008: focus on thyroid cancer management by Gramza, Ann & Schuff, Kathryn G
© 2008 Dove Medical Press Limited.   All rights reserved
OncoTargets and Therapy 2008:1 87–101 87
REVIEW
Recombinant human thyroid stimulating hormone 
in 2008: focus on thyroid cancer management
Ann Gramza1
Kathryn G Schuff  2
1Division of Medical Oncology, 
Oregon Health and Science University, 
Portland, OR USA; 2Division of 
Endocrinology, Oregon Health and 
Science University, Portland, OR USA
Correspondence: Kathryn Schuff
Division of Endocrinology L-607, 
Oregon Health and Science University, 
3181 SW Sam Jackson Park Road, 
Portland, OR 97239–3098, USA
Tel +1 503 494 1685
Fax +1 503 494 6990
Email schuffk@ohsu.edu
Abstract: Radioiodine (RAI) ablation following thyroidectomy is standard of care treatment 
for patients with intermediate or high risk differentiated thyroid cancer. Traditionally, this has 
been achieved by forgoing thyroid hormone replacement postoperatively, allowing endogenous 
thyroid stimulating hormone (TSH) levels to rise. This rise in TSH provides the stimulus for RAI 
uptake by the thyroid remnant, but is associated with clinical hypothyroidism and its associated 
morbidities. Recombinant human TSH (rhTSH, thyrotropin alfa [Thyrogen®], Genzyme Corpo-
ration, Cambridge, MA, USA) was developed to provide TSH stimulation without withdrawal 
of thyroid hormone and clinical hypothyroidism. Phase III studies reported equivalent detec-
tion of recurrent or residual disease when rhTSH was used compared with thyroid hormone 
withdrawal (THW). These trials led to its approval as an adjunctive diagnostic tool for serum 
thyroglobulin (Tg) testing with or without RAI imaging in the surveillance of patients with dif-
ferentiated thyroid cancer. Recently, rhTSH was given an indication for adjunctive preparation 
for thyroid remnant ablation after phase III studies demonstrated comparable outcomes for rhTSH 
preparation when compared with THW. Importantly, rhTSH stimulation has been found to be 
safe, well tolerated, and to result in improved quality of life. Here, we review the efﬁ  cacy and 
tolerability studies leading to the approval for the use of rhTSH in well-differentiated thyroid 
cancer management.
Keywords: recombinant human thyroid stimulating hormone, thyroid cancer, radioiodine, 
ablation, Thyrogen®, thyrotropin alfa
Introduction
The use of exogenous thyroid stimulating hormone (TSH) in the evaluation and man-
agement of thyroid cancer dates back over 50 years with the use of bovine TSH to 
stimulate iodine uptake for radioiodine (RAI) diagnostic studies and therapy. Although 
use of bovine TSH was eventually abandoned because of allergic reactions, the devel-
opment of recombinant human TSH (rhTSH, thyrotropin alfa [Thyrogen®], Genzyme 
Corporation, Cambridge, MA, USA) has dramatically changed the paradigm for the 
management and follow-up of patients with thyroid cancer. This review will introduce 
issues in the management of patients with thyroid cancer, and review the pharmacol-
ogy, mode of action, and method of administration of rhTSH. We will brieﬂ  y review 
studies of the efﬁ  cacy of rhTSH in diagnostic evaluation of thyroid cancer, and then 
focus the bulk of the review on studies of the efﬁ  cacy of rhTSH-stimulated RAI 
therapy for thyroid remnant ablation and treatment of metastases. Finally, we review 
the safety, tolerability and impact on patients’ quality of life of rhTSH preparation 
compared with thyroid hormone withdrawal (THW).
Management issues in thyroid cancer 
and use of radioiodine
Radioiodine is an important component of differentiated thyroid cancer treatment and 
surveillance. It has three main roles: 1) Ablation of residual normal thyroid tissue, OncoTargets and Therapy 2008:1 88
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2) Diagnostic scanning to detect residual/recurrent disease 
and 3) Treatment of residual/recurrent disease. Radioiodine 
administration following thyroidectomy (“remnant ablation”) 
is performed to reduce the risk of thyroid cancer recurrence 
and improve the accuracy of surveillance strategies. The 
two goals of treatment are to destroy micrometastatic or 
residual disease, and ablate remaining normal thyroid tissue 
to facilitate RAI scanning and use of Tg as a tumor marker. 
No prospective studies have been done to address the ques-
tion of which patients beneﬁ  t from this treatment strategy. 
However, based on large retrospective series, the published 
consensus guidelines from both the European Thyroid 
Association (ETA) and American Thyroid Association 
(ATA) recommend RAI ablation for patients with higher 
stage disease and recommend considering ablation in lower 
risk patients with tumors larger than 1 or 1.5 cm (Cooper 
et al 2006; Pacini et al 2006b).
The use of RAI for all three purposes relies on the abil-
ity of both normal and malignant thyroid tissue to transport 
iodine for synthesis of thyroglobulin, triiodothyronine and 
thyroxine in response to TSH. An overview of the proce-
dures for thyroid remnant ablation and diagnostic scanning 
are shown in Figure 1 and 2, respectively. TSH stimulation 
historically has been achieved by discontinuation of thyroid 
hormone replacement for 5 to 6 weeks, (thyroid hormone 
withdrawal, THW), allowing endogenous TSH levels to rise 
(Figure 1a and 1b). The optimal TSH level for ablation is felt 
to be  30 mU/L, based on a study that demonstrated that 
low TSH levels were more likely to be associated with low 
iodine uptake, which was more robust on reevaluation with 
a higher TSH (Edmonds et al 1977). In addition to high TSH 
levels, iodine depletion, such as with a low iodine diet for 1 
to 2 weeks, is important for optimal RAI uptake. If desired 
to assist in treatment decisions, diagnostic RAI whole body 
scans (WBS) are performed with a tracer dose of 74 to 185 
MBq (2–5 mCi) 131I and the diagnostic scan obtained 48 to 
72 hours later as shown in Figure 1b. Radioiodine at a dose 
of 1.1 to 3.7 GBq (30–100 mCi) is administered for remnant 
ablation, with higher doses if residual disease is known or 
suspected or the tumor has unfavorable histology or if treat-
ment of metastatic disease is planned. The patient is placed 
back on levothyroxine suppressive therapy, as appropriate, 
and approximately 1 week after the treatment dose of RAI, a 
post-therapy WBS is performed to better assess for residual 
or metastatic disease. Substitution of rhTSH stimulation for 
TSH stimulation by THW for diagnostic evaluations (shown 
in Figure 2b and reviewed by Cooper et al (2006) or for 
thyroid remnant ablation (shown in Figures 1c and 1d), has 
been published by a number of centers, allowing patients to 
remain on levothyroxine therapy and avoid the symptoms 
of hypothyroidism (Robbins et al 2001; Pacini et al 2002; 
Robbins et al 2002b; Barbaro et al 2003; Barbaro et al 2006; 
Pacini et al 2006a; Pilli et al 2007; Rosario et al 2008; Taieb 
et al 2008; Tuttle et al 2008). Over the last 3 years, thyro-
tropin alfa (Thyrogen®) has been approved for RAI ablation 
by the United States Food and Drug Administration (FDA, 
2007), in Europe (2005), and in certain Asian (2007) and 
South American countries (2006). Further discussion of 
the efﬁ  cacy of rhTSH-stimulated remnant ablation follows 
in a subsequent section. Pertinent issues include the utility 
and logistics of the diagnostic preablation scan, selection 
of the RAI therapy dose, and the extent of iodine depletion 
regimens.
Traditionally, follow-up surveillance RAI WBS and 
stimulated thyroglobulin (Tg) measurements (Figure 2) are 
performed every 12 months after remnant ablation for several 
years and then periodically. If distant metastases are discov-
ered during follow-up, patients may be incurable but can be 
retreated with various modalities (surgery, RAI) to reduce the 
tumor burden and provide a possible survival beneﬁ  t.
Thyrotropin pharmacology 
and mode of action
Thyrotropin alfa is a synthetic recombinant human thyroid 
stimulating hormone (rhTSH) produced in Chinese ham-
ster ovary cells. Although they have the same amino acid 
sequence, rhTSH differs from TSH synthesized endogenously 
by the human pituitary gland, in that rhTSH is sialylated but 
not sulfated, whereas endogenous TSH is a mixture of both 
glycosylation forms. Like the endogenous form, rhTSH 
binds to TSH receptors on normal thyroid follicular cells or 
well-differentiated thyroid cancer cells. RhTSH acts via the 
TSH receptor, a seven transmembrance G-protein coupled 
receptor, to activate the adenylate cyclase and phosphati-
dylinositol signaling pathways. TSH induces thyroid growth 
and thyroid hormone synthesis and secretion (Dumont et al 
1992). It stimulates many of the steps of thyroid hormone 
synthesis including uptake of iodide into the thyroid follicular 
cell and subsequent organiﬁ  cation of iodine at the thyroid 
follicular lumen. TSH also stimulates Tg gene expression and 
thyroid hormone secretion, involving pinocytosis of stored 
Tg into the thyroid follicular cell and limited lysosomal 
proteolysis to release T4, T3 and Tg. Because of the differ-
ences in glycosylation, rhTSH has a lower afﬁ  nity for and 
bioactivity at the TSH receptor (Szkudlinski et al 1993), but 
also a signiﬁ  cantly longer elimination half-life.OncoTargets and Therapy 2008:1 89
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A. Thyroid hormone withdrawal ablation
B. Thyroid hormone withdrawal ablation with diagonostic scan
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Figure 1 Schedules for radioiodine ablation.
Abbreviations: T3, liothyronine; TSH, thyroid stimulating hormone; RAI, radioiodine; WBS, whole body scan; Tg thyroglobulin; rhTSH, recombinant human thyroid stimulating 
hormone.OncoTargets and Therapy 2008:1 90
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Each vial of thyrotropin alfa contains 1.1 mg of rhTSH 
estimated by in vitro studies to contain 4 to 12 IU/mg. 
Immediately prior to use, it is reconstituted in 1.2 mL of 
sterile water producing a solution with a concentration 
of 0.9 mg/mL (3.6–10.8 IU). Two doses of thyrotropin 
alfa 0.9 mg (1.0 mL) are administered by intramuscular 
injection to the buttock, approximately 24 hours apart. 
For RAI imaging or remnant ablation, RAI is administered 
24 hours after the second rhTSH dose and for diagnostic 
purposes, Tg levels should be measured 72 hours after the 
last dose (Thyrogen® package insert, Genzyme Corporation, 
Figures 1 and 2). Subcutaneous injection has been studied 
in a limited number of patients (Taieb et al 2004) and is an 
alternative for patients in whom intramuscular injections 
are contraindicated.
Pharmacokinetics parameters of rhTSH administration 
were evaluated in a phase I/II study of 19 patients with well-
differentiated thyroid cancer on suppressive levothyroxine 
doses. Patients were given a variety of doses ranging from 
10 to 40 IU injected IM for 1 to 3 days, and RAI uptake and 
Tg levels were compared with those after THW. Mean peak 
TSH concentrations occurred 2 to 8 hours after each injection; 
after the 10 IU dose, peak mean TSH was 127 ± 19 mU/L and 
elevated TSH persisted for at least 48 hours after the dose 
(Meier et al 1994). The mean apparent elimination half-life 
was 25 ± 10 hours (Thyrogen® package insert, Genzyme 
Corporation). This and subsequent pharmacodynamic 
studies assessing the diagnostic use of rhTSH in thyroid 
cancer, showed that the lower dose of 10 IU was essentially 
as efﬁ  cacious and had fewer side effects than higher doses 
of 30 or 40 IU and that a regimen of 0.9 mg doses two days 
in a row results in 3–4 days of serum TSH concentration 
greater than or equal to 25 mU/L (Ladenson et al 1997; 
Haugen et al 1999).
Studies evaluating other factors affecting the pharma-
cokinetics have subsequently been done, with some show-
ing that peak TSH levels in adults are inversely related to 
body weight (Zanotti-Fregonara et al 2007), body mass 
index and body surface area (Vitale et al 2003) but others 
showing no such relationship (Montesano et al 2007) and 
one study demonstrating a positive relationship with age 
(Montesano et al 2007). However, the clinical relevance 
of such variations has not been demonstrated and no dose 
adjustment is recommended based on body weight or age. 
Although not FDA approved for use in children, studies 
in children report similar TSH levels to adults, suggesting 
A. Thyroid Hormone Withdrawal diagnostic WBS and Tg
Stop Levothyroxine (T4)
Stop liothyronine (T3) Stop liothyronine (T3)
Low iodine diet
Week: –5–6 Day: –14
T
S
H
,
 
T
h
y
r
o
g
l
o
b
u
l
i
n
T
r
a
c
e
r
 
d
o
s
e
 
R
A
I
D
i
a
g
n
o
s
t
i
c
 
R
A
I
 
W
B
S
–1 0 2–3
B. rhTSH - stimulated diagnostic WBS and Tg
Low iodine diet
r
h
T
S
H
 
I
n
j
e
c
t
i
o
n
 
#
1
r
h
T
S
H
 
I
n
j
e
c
t
i
o
n
 
#
2
T
r
a
c
e
r
 
d
o
s
e
 
R
A
I
D
i
a
g
n
o
s
t
i
c
 
R
A
I
 
W
B
S
T
g
 
m
e
a
s
u
r
e
m
e
n
t
Day: –14 1 2 3 5
Figure 2 Schedules for diagnostic radioiodine whole body scan and thyroglobulin determonation.
Abbreviations: WBS, whole body scan; Tg thyroglobulin; T4, levothyroxine; T3, liothyronine; RAI, radioiodine; rhTSH, recombinant human thyroid stimulating hormone.OncoTargets and Therapy 2008:1 91
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that dose adjustment is also not needed in this situation 
(Iorcansky et al 2005; Hoe et al 2006).
rhTSH in the diagnostic evaluation 
of thyroid cancer
Phase I/II studies demonstrated that rhTSH stimulated iodine 
uptake into thyroid cancer tissue and Tg production (Meier 
et al 1994), and two phase III studies demonstrated efﬁ  cacy 
for identiﬁ  cation of residual/recurrent disease by RAI WBS 
(Ladenson et al 1997; Haugen et al 1999). In the ﬁ  rst phase III 
study of 127 patients, rhTSH resulted in equivalent or supe-
rior RAI WBS performed after 78 to 148 MBq (2–4 mCi) 
131I in 86% of evaluations compared with THW. However, 
the rhTSH-stimulated scans were more frequently poorly 
visualized, thought to be due to more rapid renal clearance 
of iodine in the euthyroid state (Ladenson et al 1997). Out 
of 35 patients evaluated for a Tg response, 15 demonstrated 
a rise to  5 ng/mL after either rhTSH (13/15) or THW 
(14/15). Thyroglobulin levels peaked at 72 to 96 hours after 
the ﬁ  rst dose of rhTSH.
The second phase III study of 229 patients compared 
two dosing regimens, utilized a higher RAI tracer dose 
(148 MBq (4 mCi) 131I in all patients) and measured Tg 
and thryoglobulin antibodies in all patients (Haugen et al 
1999). Considering rhTSH RAI scans in both arms, 93% 
of 220 evaluable scans after rhTSH were concordant with 
or superior to those done under THW (p = 0.108). Further, 
among patients with no interfering Tg antibodies and using a 
cut-off of 2 ng/mL, there was 100% sensitivity of a rhTSH-
stimulated Tg to detect cervical lymph node and distant 
metastases and 52% sensitivity to detect residual thyroid 
remnant (similar to THW sensitivity of 56%). This study 
also demonstrated that the efﬁ  cacy with a two injection 
regimen was equivalent to a regimen of three injections over 
9 days. It was on the basis of these studies that Thyrogen® 
achieved FDA approval as an adjunctive diagnostic tool 
for Tg testing with or without RAI scanning in evaluation 
of patients with thyroid cancer.
Reproducibility of rhTSH testing has been evaluated in 
only one study of 23 patients with no evidence of disease 
by RAI scanning, Tg measurements or clinical evaluation. 
(Niederkohr and McDougall 2007) The time interval between 
the two rhTSH-stimulated evaluations was 41 months. Peak 
serum TSH was  50 mU/L in all evaluations and  100 mU/L 
in 73% of studies. There was good correlation of the 48 hour 
RAI uptake between the two studies (r = 0.85, p = 0.0001), 
peak serum TSH (r = 0.69, p = 0.0003) and Tg (r = 0.81, 
p   0.0001). However, since most evaluations showed very 
low RAI uptake and low Tg levels (mean 2.05 ng/mL), it is 
difﬁ  cult to extrapolate these results to patients with positive 
evaluations.
Recognition of the ability of rhTSH-stimulated Tg mea-
surement to identify residual/recurrent thyroid cancer with 
high accuracy and the potential for avoiding the morbidity of 
hypothyroidism associated with THW has led to a shift in the 
paradigm for the follow-up evaluation of patients with thyroid 
cancer. It is now clear that stimulated TG levels (usually 
combined with a neck ultrasound) represent the most sensi-
tive means of detecting residual or recurrent thyroid cancer. 
Speciﬁ  cally, in patients where Tg measurement was possible 
(eg, those lacking antithyroglobulin antibodies), the accuracy 
of rhTSH-stimulated Tg evaluation met or exceeded that of 
rhTSH-stimulated or even THW RAI WBS (Cailleux et al 
2000; Mazzaferri et al 2003; Pacini et al 2003; Torlontano 
et al 2003; Schlumberger et al 2004). Additionally, several 
studies demonstrated that in low risk patients, if the ﬁ  rst 
rhTSH-stimulated Tg was undetectable, the likelihood of 
thyroid cancer recurrence over 2 to 4 years was exceedingly 
small (Cailleux et al 2000; Baudin et al 2003; Castagna et al 
2008; Crocetti et al 2008). Based on this, the ATA and ETA 
guidelines recommend against RAI WBS in the routine 
follow-up of low-risk patients without evidence of disease 
(clinically and based on unstimulated Tg or ultrasound). 
Rather, unstimulated Tg and neck ultrasonography are rou-
tine in follow-up, with further stimulated Tg measurements 
and additional evaluation if indicated. Recently, highly 
sensitive (eg, functional sensitivity of 0.1 ng/mL) unstimu-
lated Tg measurements have been reported to be equally 
predictive of disease (Iervasi et al 2007; Smallridge et al 
2007), albeit in small cohorts and with only short follow-up. 
As the reliability and long-term predictive value of highly 
sensitive Tg measurements improves, this may eventually 
supplant stimulated Tg measurements for thyroid cancer 
surveillance.
One additional aspect to be considered in the evalua-
tion of patients with thyroid cancer is the utility of rhTSH 
in patients undergoing 18-fluorodeoxyglucose (18-FDG) 
positron emission tomography (PET) scanning. Detection 
of lesions by PET scanning is often complementary to that 
of RAI scanning, with more aggressive lesions having 
lost iodine avidity but demonstrating significant glucose 
uptake. In addition, PET scanning has a role in predicting 
the biologic behavior of lesions, with mortality closely 
related to volume of PET+ disease (Wang et al 2000; 
Robbins et al 2006b) which may influence therapeutic 
decisions. Several studies have demonstrated enhanced OncoTargets and Therapy 2008:1 92
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lesion detection, SUV levels and reduced background in 
PET scans performed after rhTSH stimulation, reviewed 
recently by Leboulleux et al (2007), presumably due 
to increased GLUT1 synthesis and glucose transport 
stimulated by TSH action. However, the utility of the 
incremental improvement in PET performance with 
rhTSH stimulation for affecting clinical decision making 
is not clear.
rhTSH for thyroid remnant ablation
The literature reﬂ  ects a growing experience with rhTSH for 
thyroid remnant ablation, summarized in Table 1, which 
details efﬁ  cacy results from studies that included 10 or more 
patients. Studies evaluating rhTSH for thyroid remnant 
ablation include retrospective series (with historical or 
nonrandomized THW controls), prospective consecutively 
enrolling studies (Robbins et al 2001; Pacini et al 2002; 
Robbins et al 2002b; Barbaro et al 2003; Barbaro et al 2006; 
Pilli et al 2007; Rosario et al 2008; Tuttle et al 2008) and two 
randomized trials which compared the efﬁ  cacy and safety 
of rhTSH stimulation during levothyroxine treatment with 
conventional THW remnant ablation (Pacini et al 2006a; 
Taieb et al 2008). Only one of the randomized studies and 
one uncontrolled study have reported clinical follow-up 
beyond one year (Elisei et al 2007; Tuttle et al 2008). 
Most studies utilized the schedule of rhTSH administration 
illustrated in Figure 1c.
One of the randomized trials (Taieb et al 2008) com-
pared subjects who all received 3.7 GBq (100 mCi) 131I 
after rhTSH preparation or THW. Subjects received levo-
thyroxine therapy for 1 week and then were randomized 
to either rhTSH (n = 36) or THW (n = 35) preparation for 
RAI ablation. For patients randomized to rhTSH prepa-
ration, levothyroxine was continued and rhTSH 0.9 mg 
was administered intramuscularly on 2 consecutive days. 
Twenty-four hours after the ﬁ  nal rhTSH injection, the 
ablative dose of RAI was administered. Patients random-
ized to THW discontinued levothyroxine for 5 weeks, then 
received the RAI dose. Ablation outcome was evaluated 
at 9 months post ablation with a rhTSH-stimulated RAI 
scan and Tg measurement and neck ultrasonography. No 
uptake was visible on scans in 72% of patients prepared 
by rhTSH stimulation and 91% of those prepared by 
THW (p = 0.04). However, most of the patients had a 
trivial amount of uptake, with 95% of all rhTSH stimulated 
and 100% of THW prepared patients having a RAI scan 
with  0.1% uptake (p = 0.49). A third criteria for abla-
tion success was the rhTSH-stimulated Tg measurement, 
Table 1 Studies evaluating the effectiveness of rhTSH or thyroid hormone withdrawal preparation for radioiodine ablation of thyroid 
remants
Author,   Year 
of publication
No of 
patients
131I dose Ablation outcome (visible 
uptake on RAI WBS)
Comments
rhTSH THW rhTSH THW
Robbins 2001 10 – 1.1–9.3 GBq (30–250 mCi) 100% –
Robbins 2002b 45 42 4.1 GBq (110 mCi) rhTSH 
4.8 GBq (129 mCi) THW
84% 81%
Pacini 2002 70 50 1.1 GBq (30 mCi) 54% 84% 131I given on day 4; additional 42 patients 
prepared with thyroid hormone withdrawal 
and rhTSH had a 79% ablation success
Barbaro 2003 16 24 1.1 GBq (30 mCi) 88% 75% Off LT4 × 4 days
Barbaro 2006 52 41 1.1 GBq (30 mCi) 77% 76% Off LT4 × 4 days
Pacini 2006a 32 28 3.7 GBq (100 mCi) 75% 86% Randomized
Pilli 2007 72 – 1.9–3.7 GBq (50–100 mCi) 89% –
Tuttle 2008 220 71 4.0 GBq (109 mCi) rhTSH 
3.8 GBq (103 mCi) THW
83% 76%
Rosario 2008 30 64 3.7 GBq (100 mCi) 90% 80% Ablation outcome criteria: Stim Tg  1 
and negative neck ultrasonography
Taieb 2008 36 35 3.7 GBq (100 mCi) 72% 91% Randomized
Abbreviations: rhTSH, recombinant human thyroid stimulating hormone; THW, thyroid hormone withdrawal; RAI, radioiodine; WBS, whole body scan; LT4, levothyroxine; 
Tg, thyroglobulin.OncoTargets and Therapy 2008:1 93
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which was  0.8 ng/mL in 92% of rhTSH-stimulated 
ablations and 97% of hypothyroid ablations (p = 0.61).
The other randomized trial (Pacini et al 2006a) also 
compared subjects who all received 3.7 GBq (100 mCi) 
131I after TSH stimulation preparation by rhTSH or THW. 
In this study, 33 patients were randomized to the euthyroid 
(rhTSH) group and received levothyroxine therapy for 4 to 
6 weeks until their TSH was 5 mU/L or less. RhTSH 0.9 mg 
was then given on 2 consecutive days, and 24 hours after the 
ﬁ  nal injection, the ablative dose of RAI was administered. 
Thirty patients were randomized to the hypothyroid group 
and had levothyroxine replacement withheld, and after 
4 to 6 weeks when the TSH was least 25 mU/L, they then 
received the ablative RAI dose. On a rhTSH-stimulated 
RAI scan 8 months after treatment, 24 of 32 evaluable 
euthyroid patients (75%) and 24 of 28 hypothyroid evalu-
able patients (86%) had no visible uptake (p = 0.3). Using 
a level of rhTSH-stimulated serum Tg less than 2 ng/mL 
at the 8-month point as a measure of successful ablation, 
23 of 24 evaluable euthyroid patients (96%) and 18 of 21 
evaluable hypothyroid patients (85%) were successfully 
ablated (p = 0.2).
In this same study, 61 of these patients were followed for 
a median of 3.7 years after their ablation. During that time, 
7 patients had additional therapy (surgery or RAI), 3 in the 
rhTSH ablated and 4 in the hypothyroid group. Follow-up 
evaluations revealed equivalent numbers of patients with 
“visible” (but  0.1%) uptake on RAI WBS and positive 
( 2 ng/mL) stimulated Tg measurements (1 in each group) 
(Elisei et al 2007).
The only other study reporting outcome data beyond 
one year is that of a large series of 394 patients treated 
with either rhTSH (n = 320) or THW (n = 74) preparation 
at Memorial Sloan Kettering Cancer Center (Tuttle et al 
2008). In this series, the choice of preparation was uncon-
trolled, and patients underwent ablation with the RAI 
dose determined according to clinical features, histologic 
ﬁ  ndings, intraoperative ﬁ  ndings, risk of recurrence and 
results of a diagnostic I-123 WBS, regardless of method of 
preparation (rhTSH or THW). Ablative RAI doses ranged 
from 2.7–3.7 GBq (75–100 mCi) 131I for intrathyroidal papil-
lary thyroid carcinoma, 3.7 to 5.5 GBq (100–150 mCi) for 
patients with cervical lymph node metastases and  5.5 GBq 
(150 mCi) if locally aggressive disease or known distant 
metastases were present. Patients who underwent rhTSH-
stimulated ablation received a median of 109 mCi compared 
with THW patients who received a median of 103 mCi 131I 
(p   0.01), median age was slightly higher in the rhTSH 
group (46.5 years vs 44.0 years, p = 0.03) and median 
follow-up duration was shorter (27 months vs 45 months, 
p   0.001); other characteristics of the patients were 
not different between the groups. Ablation success was 
evaluated in 291 of the subjects who underwent a follow-up 
rhTSH-stimulated RAI WBS at 12 to 18 months. Successful 
ablation deﬁ  ned as no visible uptake on the RAI WBS was 
achieved in 83% of rhTSH stimulated ablations and 76% 
of THW prepared patients. Using a deﬁ  nition of  0.1% 
uptake, successful ablation was achieved in 95% of those 
undergoing rhTSH ablation and in 90% of THW prepared 
patients (p = 0.35). Suppressed and stimulated Tg levels 
were not different between the groups at the 12 to 18 
month follow-up; 68.6% of rhTSH-prepared patients had a 
stimulated Tg   2 ng/mL compared with 61.9% of THW 
prepared patients (p-value not signiﬁ  cant, Tuttle, personal 
communication).
Follow-up of this cohort was for a median of 2.5 years 
and the authors reported four clinical outcomes: no clini-
cal evidence of disease (NCED: negative rhTSH WBS, 
no clinical recurrence, suppressed Tg   2 ng/mL and 
stimulated  10 ng/mL), clinical recurrence (new disease 
after a period of NCED), persistent disease (suppressed 
Tg   2 ng/mL or stimulated  10 ng/mL 1 year after abla-
tion, persistent anatomic disease, new metastasis within six 
months of ablation or known distant metastases at diagnosis) 
and thyroid bed uptake only (persistent at 12- to 18-month 
follow-up with no other Tg or ultrasonographic evidence 
of disease). There were more treatment failures in patients 
prepared by THW (p = 0.02), but equivalent numbers of 
patients in the two groups when considering only patients 
without distant metastases. This lends reassurance that the 
initial favorable response to rhTSH-stimulated remnant 
ablation is durable.
In summary, data on almost 600 patients have been 
reported in several uncontrolled studies and two relatively 
small randomized controlled trials, demonstrating that 
rhTSH stimulation for RAI thyroid remnant ablation is 
successful in about 80% to 90% of patients, comparable 
to rates seen with THW preparation. In December of 
2007, the FDA approved Thyrogen® for use “as an 
adjunctive treatment for RAI ablation of thyroid tissue 
remnants in patients who have undergone a near-total 
or total thyroidectomy for well-differentiated thyroid 
cancer and who do not have evidence of metastatic 
thyroid cancer.” It should be noted, that the patients who 
participated in these studies were generally patients with 
low stage disease, and because of concern about lower OncoTargets and Therapy 2008:1 94
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RAI uptake from early studies with rhTSH, care should 
be taken when evaluating patients for selection for rhTSH 
stimulated ablation.
Optimal radioiodine dose and other 
factors important for successful 
thyroid remnant ablation under 
rhTSH stimulation
The issue of the minimum adequate dose required for 
remnant ablation has been a controversial one even prior 
to the use of rhTSH preparation. The efﬁ  cacy of doses 
lower than 3.7 GBq (100 mCi) 131I for ablation of thyroid 
remnants with rhTSH preparation has been examined in 
four studies and is compared to that reported in studies 
using greater than 3.7 GBq (100 mCi) 131I, all of which 
are summarized in Table 2. One of these was a random-
ized trial that compared 1.9 GBq (50 mCi) with 3.7 GBq 
(100 mCi) (Pilli et al 2007). This study as well as 2 of 
the 3 uncontrolled studies utilizing 1.1 GBq (30 mCi) 
(Pacini et al 2002; Barbaro et al 2003; Barbaro et al 2006) 
reported 77% to 89% ablation rates, deﬁ  ned as no visible 
uptake on a WBS, similar to the 6 studies administering 
3.7 GBq (100 mCi) or more which had ablation rates from 
72% to 89% (Robbins et al 2002b; Pacini et al 2006a; 
Rosario et al 2008; Taieb et al 2008; Tuttle et al 2008). 
The third uncontrolled study of 1.1 GBq (30 mCi) found 
a lower ablation rate (54%); however, the investigators 
utilized a different schedule of rhTSH administration, 
which may have compromised iodine uptake.
Compared with THW, renal clearance of RAI is not 
reduced when rhTSH is used. For this reason, the use of a 
low iodine diet to deplete iodine stores and/or evaluation of 
urinary iodine excretion has been routinely done in these 
studies. An additional source of iodine is that contained 
in thyroid hormone replacement preparations. Therefore, 
the impact of continuing thyroid hormone preparations 
on the efﬁ  cacy of rhTSH ablation has also been studied 
(Barbaro et al 2003). This study demonstrated that omission 
of levothyroxine for 4 days reduced urinary iodine, but 
urinary iodine was not different in another study between 
hypothyroid and euthyroid subjects where levothyroxine was 
continued (Pacini et al 2006a). Further, in these studies, it 
did not appear that discontinuing thyroid hormone improved 
ablation rates compared to studies that allowed patients 
to continue their thyroid hormone replacement. However, 
no study has evaluated this question in a single study in a 
randomized fashion.
In summary, the limited data available suggests that doses 
of RAI less than 3.7 GBq (100 mCi) 131I may indeed be as 
efﬁ  cacious as higher doses. Short term discontinuation of 
thyroid hormone preparations does not appears to improve 
ablation rates, but may warrant evaluation in additional 
patient populations in a randomized study. Finally, the timing 
of RAI administration in relation to rhTSH stimulation may 
be a critical factor.
Logistic issues with rhTSH 
stimulated thyroid remnant 
ablation
The studies summarized above generally used a standard 
schedule of administering rhTSH on days 1 and 2, then giving 
the ablative RAI on day 3 when TSH levels are at their peak, 
which should be optimal for RAI uptake into the thyroid gland. 
However, this schedule is problematic if one needs to obtain 
a diagnostic scan before administering the therapeutic RAI 
dose. When a diagnostic scan is indicated to assist in ablative 
dosage selection or as a baseline for comparison to future 
scans, various schedules have been proposed to circumvent 
this problem. These include administering a tracer dose 
of 123I (which has a shorter half-life) on day 3, which allows 
an 123I diagnostic scan to be performed prior to an 131I abla-
tion dose given the same day. Alternatively some clinicians 
perform either an 123I or 131I scan on days 3 and 4, and delay 
administration of the ablative 131I dose until day 4, 2 days after 
the last rhTSH dose. This has the disadvantage of delaying 
RAI therapy until day 4 when TSH levels have decreased 
signiﬁ  cantly, thereby potentially lowering treatment efﬁ  cacy. 
Only one study has speciﬁ  cally reported ablation rates with 
this schedule and found that only 54% of patients were ablated 
when given 1.1 GBq (30 mCi) 131I on day 4 after rhTSH 
(Pacini et al 2002). Whether this lower rate was related to the 
lower RAI dose or the later RAI administration is not clear, 
however, other studies with 1.1 GBq (30 mCi) 131I (includ-
ing studies from the same group) have signiﬁ  cantly higher 
ablation rates (see previous section and Table 2 for details). 
The value of the diagnostic scan prior to ablation has been 
questioned and 1 study has demonstrated that the diagnostic 
scan rarely assists in managing the patient (Mandac et al 
2008). Most providers feel the value of the diagnostic scan is 
minimal and perform only a post-therapy scan approximately 
1 week after the ablative dose. Alternatively, if the diagnostic 
scan is felt to be critical to decision-making, a second course 
of rhTSH stimulation can be administered the week following 
the diagnostic scan, ensuring adequate TSH stimulation for 
remnant ablation (as show in Figure 1d).OncoTargets and Therapy 2008:1 95
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A second logistic issue with rhTSH stimulated ablation 
is the timing of the measurement of the rhTSH-stimulated 
Tg levels. Several studies have shown the predictive value 
of the post-thyroidectomy, preablative stimulated Tg level 
(Grunwald et al 1996; Toubeau et al 2004; Kim et al 2005). 
However, pharmacodynamic studies of rhTSH for diagnostic 
uses demonstrated that the peak Tg level in response to rhTSH 
occurred on day 5 after the 2 rhTSH injections (Ladenson et al 
1997; Haugen et al 1999). This is after the ablative dose of 
RAI, which could impact Tg levels on the basis of radiation-
induced tumor lysis. One study examined the effect of this 
intervening ablative dose of RAI on Tg levels and found that 
Tg levels increased after RAI therapy due to acute radiation 
effects (Taieb et al 2006). Because of the two simultaneous 
stimuli to Tg levels, rhTSH and RAI tumor destruction, this 
paradigm would not result in Tg levels that would be compa-
rable to values obtained in diagnostic settings. Other clinicians 
draw a Tg on day 3, just before the ablative RAI dose, but this 
is less predictive because of the difference in timing of the Tg 
level in relationship to rhTSH. Further studies will be needed 
to determine if this measurement has any clinical utility.
Utility of rhTSH for radioiodine 
treatment of metastatic thyroid 
cancer
The ﬁ  rst report of RAI treatment of metastatic thyroid cancer 
using rhTSH stimulation dates back to 1997 (Rudavsky and 
Freeman 1997). Concern about the efﬁ  cacy of this approach 
stems from observations of lower apparent RAI uptake 
observed in the early phase diagnostic studies, thought to be 
due to more rapid iodine clearance in euthyroid patients (Park 
et al 1996; Ladenson et al 1997). However, the impact of this 
biologic measure on the ultimate clinical outcome, effective 
treatment of the metastatic deposits, is less clear. Although 
lower iodine uptake has been shown to lack clinical signiﬁ  -
cance for thyroid remnant ablation, described in the previous 
section, it may be more relevant in treating metastatic disease 
due to the impaired iodine uptake and organiﬁ  cation observed 
in carcinomatous tissue compared with normal thyroid tis-
sue (Schlesinger et al 1989). Thyrogen® is FDA approved 
as an adjunct to RAI treatment of metastatic thyroid cancer 
only in patients who are either unable to mount an adequate 
endogenous TSH response to THW or in whom THW is 
medically contraindicated, as options are otherwise limited 
in that patient population. Although there are no randomized 
trials comparing rhTSH stimulated RAI treatment to THW 
prepration, data from this “compassionate use” population 
and other case series (Luster et al 2000; Mariani et al 2000; OncoTargets and Therapy 2008:1 96
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Lippi et al 2001; Pellegriti et al 2001; Berg et al 2002; de 
Keizer et al 2003; Jarzab et al 2003; Robbins et al 2006a), 
summarized in Table 3, provide some information about the 
effectiveness of this approach. Unfortunately, the literature 
is heterogeneous and limited in particular by the lack of 
outcome data. Further, the interpretation of this literature is 
difﬁ  cult given the relative lack of comparable data for the 
efﬁ  cacy of RAI therapy prepared by THW, with reports rang-
ing from 20% to 90% (Maxon et al 1992; Pacini et al 1994; 
Alzahrani et al 2002; Robbins et al 2002a; Dam et al 2004; 
Rosario et al 2004; Kloos and Mazzaferri 2005).
Despite these limitations, almost all of the listed studies 
report uptake on post-therapy scans in a majority of patients, 
providing reasonable evidence for rhTSH stimulation of 
iodine uptake in metastatic deposits. Further, two studies 
compare the rhTSH scans to prior hypothyroid scans favor-
ably, with concordant or superior rhTSH scans in 82% to 
90% of patients (Lippi et al 2001; Jarzab et al 2003). How-
ever, even though some uptake is observed after rhTSH, 
the concern remains that since lower RAI uptake has fairly 
consistently been observed in several studies (Park et al 1996; 
Ladenson et al 1997; Pacini et al 2002; Luster et al 2003; 
Hanscheid et al 2006; Potzi et al 2006; Vaiano et al 2007), 
the radiation dose to the tumor may be reduced in patients 
treated with rhTSH. This has been examined in several 
dosimetric studies, summarized in Table 4. The methods and 
reported parameters (eg, initial dose rate, effective half-life, 
residence time, cumulative activity) across the studies are 
quite heterogeneous. In addition, the conclusions in regard 
to effective radiation dose are mixed, with 3 of 6 studies 
showing a reduced radiation dose to the thyroid remnant or 
tumor (Pacini et al 2002; Potzi et al 2006; Vaiano et al 2007), 
2 showing an increased radiation dose (Luster et al 2003; 
Hanscheid et al 2006) and 1 estimating the dose to be the 
same as historical hypothyroid-prepared patients (de Keizer 
et al 2003). Also potentially concerning is that the studies 
summarized in Table 3 include few reports of complete 
remission with rhTSH-stimulated treatment, even by surro-
gate markers such as Tg or follow-up RAI scans, and there 
is even a low rate of partial responses. However, in many of 
the series, the patient populations had very advanced disease, 
such that complete or partial responses might not be expected, 
and stable disease would be considered to represent a clinical 
beneﬁ  t to the patient.
Safety and tolerability
In clinical trials rhTSH for both diagnostic and thera-
peutic purposes, the incidence of side effects was low. 
Combined data from clinical trials leading to FDA 
approval reveal the most common adverse events to be 
nausea (11.9%) and headache (7.3%) (Thyrogen® package 
insert, Genzyme Corporation). According to the Genzyme 
package insert, post-marketing experience has shown 
that administration of rhTSH can cause transient ﬂ  u-like 
symptoms for up to 48 hours. Hypersensitivity has also 
been reported in patients with advanced disease, as mani-
fested by urticaria, rash, pruritis, ﬂ  ushing, and respiratory 
symptoms. Similar to THW, there are case reports of tumor 
enlargement, edema, and hemorrhage resulting in pares-
thesias, hemiplegia, pathologic vertebral fractures, neck 
edema as well as exacerbation of bone pain seen within 
12 to 48 hours of rhTSH administration (Vargas et al 1999; 
Robbins et al 2000; Braga et al 2001; Lippi et al 2001; 
Berg et al 2002; Goffman et al 2003; Jarzab et al 2003). 
For this reason, it is recommended that pretreatment with 
glucocorticoids be considered in patients with tumors 
located where transient expansion may compromise vital 
anatomic structures (eg, CNS and spinal metastases, bulky 
neck metastases). It is also recommended that patients who 
have extensive functional thyroid tissue or cardiac condi-
tions (for whom rhTSH-induced stimulation of thyroid 
hormone production causing hyperthyroidism could have 
serious consequences) be hospitalized for administration 
and observation.
One potential advantage to rhTSH stimulation may 
be lower radiation exposure. Since there is reduced renal 
clearance of iodine and longer retention of the RAI in 
hypothyroid patients, preparation with rhTSH allows 
patients to remain euthyroid and potentially clear their 
radiation dose faster. Several recent studies have examined 
this issue and are summarized in Table 4. The methods 
across the studies are quite heterogeneous and not all studies 
reported both blood and whole body exposure. However, all 
studies that report either blood or red marrow doses, whole 
body retention times or residence times show the radiation 
exposure to be reduced by 10%– 35% when prepared with 
rhTSH preparation rather than THW (Pacini et al 2002; 
de Keizer et al 2003; Luster et al 2003; Menzel et al 2003; 
de Keizer et al 2004; Hanscheid et al 2006; Potzi et al 2006; 
Vaiano et al 2007).
Quality of life
As mentioned previously, rhTSH was developed to avoid the 
consequences of prolonged hypothyroidism, and the negative 
impact of symptoms of hypothyroidism on patient quality 
of life. The impact of treatment on quality of life has been OncoTargets and Therapy 2008:1 97
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assessed in several of the randomized prospective efﬁ  cacy 
trials comparing rhTSH with THW. In all studies that report 
it, quality of life by a variety of measures (hypothyroid 
symptoms and signs by the self-reported Billewicz scale 
or a validated hypothyroid clinical questionnaire; global 
quality of life by SF-36 health survey or a cancer speciﬁ  c 
survey; mood by various inventories) reveal increased 
symptoms and decrements in quality of life with THW 
preparation that is prevented by preparation with rhTSH 
instead (Botella-Carretero et al 2003; Giusti et al 2005; 
Table 3 Studies evaluating the effectiveness of rhTSH for 131I treatment of metastatic disease after prior thyroidectomy
Author, year 
of publication
No of patients 
(No treatments,
if  1/patient)
131I dose Treatment outcome Comments
Uptake on 
post-therapy 
scan
Tg response Clinical/imaging 
response
Luster 2000 11 (16) 1–7.4 GBq 
(27–200 mCi)
NR 5/11 PR 2/11 PR Advanced disease in 90% Tg 
response:  30% decrease
2/9 SD
3/11 SD 3 dead of PD
Mariani 2000 8 7/8 No uptake due to iodine 
contamination in 1 patient
Pellegriti 2001 6 3.7 GBq (100 mCi) 4/6 NR 1/4 PR 2 patients with negative 
WBS also had low 
stimulated Tg; may have 
been with no or no 
signiﬁ  cant disease
3/4 SD
Lippi 2001 12 0.1–0.11 GBq/kg 
2.7–3.0 mCi/kg
12/12 4/10 PR 2/5 Comparison to prior THW 
scan concordant in 67%, 
superior in 33%
2/10 SD
4/10 PD
Berg 2002 8 (11) 4.0 GBq (108 mCi) 9/11 1/7 PR 5/7 PR
3/7 SD 2 NED
3/7 PD
De Keizer 2003 16 7.4 GBq (200 mCi) 18/19 3/11 PR NR Tg Response:  25% 
decrease, increase
2/11 SD
6/11 PD
Jarzab 2003 31 (54) 3.7–7.4 BGq 
(100–200 mCi)
25/30 Imaging and Tg Response
1/47 CR
12/47 PR
19/47 SD
14/47 PD
Negative uptake reported 
to be due to CR in 3, 
dedifferentiation in 2
Comparison to prior 
hypothyroid scan con-
cordant in 67%, superior 
in 15%, inferior in 19% 
(attributed to clinical causes, 
not differences in rhTSH vs 
THW preparation)
Comparison to prior 
THW outcome of therapy 
identical in 52%; superior in 
32%, inferior in 16%
Robbins 2006a 115 (NR) NR 105/115 
Diagnostic or 
post-therapy
48%–73% PR 25% improved
55%–60% no 
change
15%–20% worse
Abbreviations: rhTSH, recombinant human thyroid stimulating hormone;   Tg, thyroglobulin; NR, not reported; PR, partial response; SD, stable disease; PD, progressive disease; 
WBS, whole body scan; THW, thyroid hormone withdrawal; NED, no evidence of disease; CR, complete remission.OncoTargets and Therapy 2008:1 98
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Mernagh et al 2006; Pacini et al 2006a; Schroeder et al 2006; 
Borget et al 2007; Taieb et al 2008).
Other groups have sought to correlate these improve-
ments in morbidity with increased productivity and economic 
outcomes. In one study, THW resulted in a median of 11 days 
of missed work (Luster et al 2005), which was equivalent to 
the cost of administering rhTSH. A recently published study 
from Europe looked at sick leave as an indirect measure of 
morbidity. From the 306 patients included, 292 (95%) com-
pleted a questionnaire detailing their treatment, economic and 
sick leave data. They found there were 194 actively working 
patients among this group. Those who were treated with rhTSH, 
when compared to those treated by THW, were less likely to 
require sick leave (11% vs 33%, p = 0.001). Among those who 
did require sick leave, the mean duration was shorter (3.1 vs 
11.2 days, p = 0.002) (Borget et al 2007).
Because of the faster clearance of RAI when patients 
are euthyroid receiving rhTSH and anecdotal reports of 
shorter hospital admissions for RAI therapy, Borget also 
evaluated a potential impact on length of hospital stay with 
Table 4 Studies reporting dosimetric evaluation of thyroid remnant, metastatic tumor, blood and whole body radiation exposure after 
rhTSH compared to thyroid hormone withdrawal preparation
Author, year of publication No of patients 
(No evaluations)
Summary of ﬁ  ndings 
related to dose to 
 remnant
Summary of ﬁ  ndings 
related to blood and whole 
body exposure
Pacini 2002 70 rhTSH 42 THW Mean initial dose rate 1
0.7 Gy/h after rhTSH vs 
27.1 Gy/h; 60.5% lower 
than THW Cumulative 
dose could not be assessed 
because effective half-life was 
not measured.
NR
De Keizer 2003, 2004 16 (19 Rx) Tumor effective half-life 65 h, 
similar to previous report of 
79 h for THW
Blood dose 0.23 mGy/MBq
Red marrow dose 
0.16 mGy/MBq, below 2 Gy 
in all patients given 7.4 GBq
26% lower than historical 
hypothyroid preparation
Luster 2003 9 Tumor effective half-life 
longer than THW
Tumor residence time 
increased 5.7 ± 6.3 fold after 
rhTSH
Blood effective half-life 25% 
shorter, blood dose 10% lower
Whole body exposure 22% 
lower
Menzel 2003 38 rhTSH (64 Rx) 
103 THW (163 Rx)
NR Whole body effective half-life 
0.43 d after rhTSH vs 0.54 d; 
20%–25% shorter than THW
Hanscheid 2006 33 rhTSH 30 THW Remnant effective half-life 
68 h after rhTSH vs 48; 40% 
longer than THW
Tumor residence time 1.4 h 
after rhTSH vs 0.9; 60% 
longer than THW
Blood dose 0.109 mGy/MBq 
after rhTSH vs 0.167 mGy/MBq; 
35% lower than THW
Whole body residence time 
17.3 h after rhTSH vs 24.1 h; 
28% shorter than THW
Potzi 2006 4 Median tumor half-life 22 h 
after rhTSH vs 40 hr THW; 
45% shorter than THW
Mean cumulative activity 
5.6 uCi/hr after rhTSH vs 
9.5 uCi/h; 41% lower activity 
than THW
Vaiano 2007 17 rhTSH 21 THW Mean cumulative activity 
0.9 h after rhTSH vs 1.55 h; 
40% lower than THW
Red marrow dose 0.06 mGy/MBq 
after rhTSH vs 0.09 mGy/MBq; 
33% lower than THW
Abbreviations: rhTSH, recombinant human thyroid stimulating hormone; THW, thyroid hormone withdrawal; NR, Not reported; Rx, treatments.OncoTargets and Therapy 2008:1 99
Review of RhTSH in 2008
a case-control study. Thirty-ﬁ  ve rhTSH-prepared patients 
were matched to 64 THW patients on factors affecting RAI 
clearance. The modeled simulations predicted a length of 
stay of 2.4 days for patients who received rhTSH preparation 
compared to 3.5 days for THW preparation (p   0.001). 
This resulted in a savings of  338, which would defray 
approximately half the cost of thyrotropin alfa administra-
tion (Borget et al 2008).
An economic analysis from a societal perspective evalu-
ated quality of life improvements from avoiding hypothy-
roidism, increased work productivity, earlier discharge from 
a radiation safety perspective and theoretical reduction in 
risk of secondary malignancy. Utilizing a lifetime Markov 
model expressing beneﬁ  ts in terms of quality adjusted life-
years (QALY), this analysis found the additional beneﬁ  ts of 
rhTSH to patients and society at relatively modest net cost 
(Mernagh et al 2006).
In summary, there is no question that rhTSH-stimulated 
preparation for diagnostic and therapeutic procedures in 
thyroid cancer improves patient quality of life, reduces 
sick time and potentially reduces some direct costs such as 
hospitalization for radioprotection. Further, quality of life 
and productivity end-points are particularly important for 
thyroid cancer patients, since thyroid cancer often strikes 
young adults, with a median age of presentation of 48 years 
and about 80% of patients presenting between the ages of 
21 and 65 (SEER 2008).
Summary
Clearly, development of rhTSH has dramatically changed 
the initial management and follow-up of patients with 
well-differentiated thyroid cancer. There is clear evidence 
that preparation of patients for RAI ablation of thyroid 
remnants is as efﬁ  cacious as THW in low risk patients, at 
least for 2 to 3 years of follow-up. In addition, diagnostic 
follow-up evaluations with rhTSH-stimulated Tg are as 
informative as THW WBS and Tg measurements. Evalu-
ation of this follow-up paradigm has been accompanied 
by a reconsideration of the role of RAI WBS and a shift 
to recommendations of rhTSH-stimulated Tg and neck 
ultrasonography as the primary modalities of follow-up. 
The use of rhTSH preparation in these situations and 
avoidance of hypothyroid symptoms and complications is 
cost-effective, or even cost-saving (in some macroeconomic 
models of health care and medical leave coverage). Further, 
limited studies suggest that whole body and blood radiation 
exposure from RAI may be lower after rhTSH preparation 
due to faster renal clearance of iodine, which, theoretically, 
may reduce long-term complications such as permanent 
sialoadenitis (Mandel and Mandel 2003) and secondary 
malignancies (Rubino et al 2003; Sandeep et al 2006; 
Brown et al 2008).
Unresolved issues remain in regard to the deﬁ  nitive 
minimal efficacious dose of RAI for remnant ablation, 
conﬁ  rmation of the long-term durability of the ablation 
success with rhTSH, determining optimal paradigms for initial 
diagnostic WBS and Tg determinations, and determining the 
required frequency of follow-up stimulated Tg measurements 
in low risk patients.
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